July 18, 2025

Decade of Data Validates Life’s Simple 7

A decade-long review supports that higher Life’s Simple 7 cardiovascular health scores significantly reduce risks of chronic disease, mortality, and health care use.

Conexiant

July 17, 2025

Nirsevimab Shows 83% Efficacy Over 6 Months

A large clinical trial in Europe showed that a single dose of nirsevimab reduced infant hospitalizations for RSV-associated lower respiratory tract infections by over 80% over a six-month period.

Conexiant

July 17, 2025

Cancer History Linked to Severe COVID-19, Study 

Adult childhood cancer survivors had a higher risk of severe COVID-19 despite lower infection rates and higher vaccination coverage.

Conexiant

July 15, 2025

U.S. Children’s Health Worsens Over 17 Years

A new study analyzing over a decade of national health surveys, electronic records, and international data shows a consistent rise in chronic conditions, obesity, emotional symptoms, and mortality rates among children and adolescents in the U.S..

Conexiant

July 15, 2025

Hospital Violence Program Shows No Reinjury Gain

Researchers evaluate the Life Outside of Violence program and find no significant reduction in youth reinjury risk after violent trauma.

Conexiant

July 10, 2025

1 in 4 U.S. Infants Missing Bifidobacterium: Study

Babies who lacked this key gut bacteria were at an increased risk of eczema, allergies, and asthma by age 2.

Conexiant

July 09, 2025

E. coli Upcycle Turns Plastic to Pills

Scientists engineered E. coli to perform a synthetic chemical reaction that enables the conversion of plastic waste into the common drug paracetamol using a non-toxic, phosphate-driven process inside living cells.

Conexiant

July 07, 2025

FDA Approves First Oral Hereditary Angioedema Treatment

FDA approves Ekterly (sebetralstat), the first oral on-demand treatment for hereditary angioedema, shown in trials to provide faster symptom relief and eliminate the need for injection.

Conexiant

July 02, 2025

FDA Approves Ready-to-Infuse Vancomycin

Tyzavan is the first FDA-approved vancomycin formulation available at room temperature that requires no compounding, thawing, or dilution, enabling faster treatment in time-critical infections like sepsis.

Conexiant